Table 1.
Patient characteristics
| 6 FEC 100 | 3 FEC/3D | |
| Total number of patients (154) | 84 | 70 |
| Median age (range) | 43.5 (28–58) | 44 29–53) |
| Patients < 40 years (n = 39) | 18 (21.5 %) | 21 (30 %) |
| Patients ≥ 40 years (n = 115) | 66 (78 %) | 49 (70 %) (p = 0.08) |
| Hormone receptor status | ||
| Positive (ER and/or PR) | 61 (72.6 %) | 53 (75.9 %) |
| Negative (ER and PR) | 23 (27.4 %) | 17 (24.1 %) |
| ER positive | 60 (71.4 %) | 52 (74.2 %) |
| ER negative | 24 (28.5 %) | 18 (25.7 %) |
| PR positive | 50 (59.5 %) | 44 (62.8 %) |
| PR negative | 34 (40.4 %) | 26 (37.1 %) |
| Median tumor size (range) | ||
| Tumor grade | ||
| I | 8 (9.5 %) | 6 (8.6 %) |
| II | 34 (40.5 %) | 30 (42.8 %) |
| III | 42 (50 %) | 34 (48.6 %) |
| Number of metastatic lymph nodes | ||
| < 4 | 66 (78.6 %) | 53 (75.9 %) |
| ≥ 4 | 18 (21.4 %) | 17 (24.1 %) |
| Tumor size | ||
| T1 | 25 (29.7 %) | 21 (30 %) |
| T2 | 50 (59.5 %) | 42 (60 %) |
| T3 | 9 (10.8 %) | 7 (10 %) |
ER: estrogen receptor; PR: progesterone receptor
(p-value never < 0.05)